Natera, Inc. · NASDAQ:NTRA
Natera — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
16 slides from Natera's conference presentation, Jan 9, 2024
Slide 1: Natera, Inc. Investor presentation
Natera, Inc. Investor presentation J.P. Morgan Healthcare Conference January 9, 2024
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity,our an
Slide 3: A leader in cell-free DNA technology addressing large, underpenetrated markets
A leader in cell-free DNA technology addressing large, underpenetrated markets tests >10M processed 2013 2019 Panorama NIPT launch 12 products ONCOLOGY peer-reviewed ~175 publications WOMEN’S HEALTH issued or >400 pending patents ORGAN HEALTH >3,200 employees NOTE: All numbers are as of Dec. 31, 202
Slide 4: Formula for success
Formula for success Leading-edge Excellent customer/ technology + patient experience constant innovation Broad and talented Leader in peer-reviewed, commercial teams published clinical data 4 Not for reproduction or further distribution.
Slide 5: Results preview: 2023 revenues ~$20M above top of guide
Results preview: 2023 revenues ~$20M above top of guide • Preliminary Q4 total Total revenues: year-on-year trend revenues deliver ~38% ($ in millions) ~$300M growth YoY • Signatera continues to $217M ramp $173M • Significant ASP $112M momentum $83M $67M • Strong gross margin performance in Q4 Q4'18
Slide 6: Continued volume momentum in FY2023
Continued volume momentum in FY2023 • Robust volume Tests processed: year-on-year trend 3,000K growth 2,490K 2,500K • Signatera volumes continue strong 2,070K 2,000K sequential quarterly growth 1,570K 1,500K trends 1,030K • Focus on profitable 1,000K 670K 800K growth in Women’s 500K Health driving A
Slide 7: Reduced annual cash burn by ~$200 million in 2023
Reduced annual cash burn by ~$200 million in 2023 Quarterly cash burn trend • Executing the strategy: cash burn ($ in millions) reduction driven by continued revenue $180 growth, improving gross margins, and $162 1 stable operating expenses. $160 $140 • Q4 estimate of approximately $60 $120 $110 $11
Slide 8: Market leadership in oncology MRD
Market leadership in oncology MRD $20B >60 35% estimated TAM peer-reviewed of oncologists ordered studies Natera’s tests >300K >150K >400 tests performed patients in our clinical- commercial operations in 2023 genomic database and medical affairs employees NOTE: 35% of oncologists ordered Natera’s t
Slide 9: Signatera sample report
Signatera sample report Easy-to-interpret longitudinal report for molecular monitoring • Positive/negative results to inform adjuvant treatment decisions and detect recurrence early • Quantitative ctDNA dynamics to assess whether tumor is growing or shrinking in response to treatment • Pan-cancer •
Slide 10: Significant first mover advantages
Significant first mover advantages Innovation & Market access & Laboratory & Clinical data Intellectual Property reimbursement customer experience • Cutting-edge test • >60 peer-reviewed • Broad Medicare • Fast TAT, mobile phleb, performance publications to date, coverage with CRC, portals, EMR, tis
Slide 11: Market leader in women's health genetic testing
Market leader in women’s health genetic testing >$10B >5M estimated TAM NIPT tests performed since launch of Panorama 85 ~1 in 2 peer-reviewed publications NIPTs in US ordered with >2M patients from Natera1 1. Internal market research and claims data analysis using Definitive Healthcare data set. Ju
Slide 12: Panorama screening for 22q is highly differentiated
Panorama screening for 22q is highly differentiated Proprietary SNP-based NIPT technology allows for high sensitivity and PPV Analytical performance Clinical performance Clinical utility p arm 22q11.2 region q arm • SMART trial1 enrolled >20,000 • Early intervention can improve outcomes pregnant wom
Slide 13: Innovative solutions in organ health
Innovative solutions in organ health Transplant Chronic Kidney Disease Donor cfDNA assessment to Genetic testing for chronic detect active rejection kidney disease ~50% >55% of kidney, heart and lung of nephrologists transplant centers ordered ordered Renasight Prospera commercially >30 >1 in 71 pee
Slide 14: Publication of landmark RenaCARE study
Publication of landmark RenaCARE study1 Real-world, prospective study of 1,600+ patients with CKD Broad utility for testing: ~1 out of 5 patients had a positive genetic finding • Unknown causes of CKD • Disease subtyping: PKD1/PKD2 • Non-specific diagnoses, i.e. diabetes, hematuria, hypertension, et
Slide 15: Upcoming potential catalysts
Upcoming potential catalysts Natera today Large potential catalysts • Strong revenue growth driven by volumes and ASPs • Guideline inclusion of women’s health products • On track for cash flow break even quarter in 2024 • Readout of multiple randomized trials, including regardless of any catalysts A
Slide 16: ©2024 Natera, Inc. All Rights Reserved. Not for reproduction or further distribution.
® ©2024 Natera, Inc. All Rights Reserved. Not for reproduction or further distribution. 16
Natera — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix